Form 4: Harmony Biosciences CFO Sandip Kapadia Executes Stock Transactions
SEC Form 4 Filing
Sandip Kapadia, CFO of Harmony Biosciences Holdings, Inc., reports transactions involving common stock and derivative securities, including the vesting and sale of restricted stock units.
Summary
- On January 24, 2025, Sandip Kapadia, CFO of Harmony Biosciences Holdings, Inc., executed multiple transactions involving the company's common stock.
- These transactions included the vesting of 3,812 restricted stock units, the withholding of 2,037 shares to cover income tax obligations, and the sale of 1,775 shares at a weighted average price of $38.0548.
- Kapadia also acquired 66,250 stock options and 18,900 restricted stock units on January 25, 2025.
- Following these transactions, Kapadia directly owns 0 shares of common stock, 66,250 stock options, and 18,900 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.
Future Outlook
The stock options vest with respect to 25% of the underlying shares on January 25, 2026, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common for executives of publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies and their executives.
- The vesting schedules for the stock options and restricted stock units are typical, with vesting occurring over a multi-year period.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares by the CFO.
- The vesting of stock options and restricted stock units incentivizes the CFO to continue service with the company.
Key Dates
| Date | Description |
|---|---|
| 01/24/2024 | Date of previous grant of restricted stock units. |
| 01/24/2025 | Vesting of restricted stock units, withholding of shares for taxes, and sale of shares. |
| 01/25/2025 | Grant date of stock options and restricted stock units. |
| 01/25/2026 | Vesting start date for stock options and restricted stock units granted on January 25, 2025. |
| 01/27/2025 | Sale of 1,775 shares at a weighted average price of $38.0548. |
| 01/28/2025 | Date of Form 4 filing. |
| 01/25/2035 | Expiration date of stock options granted on January 25, 2025. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.